<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231001120910&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4 Z_t ESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;v=2.17.9。邮政6 +86293ac<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231001120910&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 10 月 1 日，星期日 16:09:13 +0000</lastbuilddate><pubDate> Sat, 30 Sep 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>基于 AsCas12f 的紧凑型基因组编辑工具，由深度突变扫描和结构分析衍生而来</title><link/>https://pubmed.ncbi.nlm.nih.gov/37776859/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231001120910&amp;v=2.17.9.post6+86293ac<description> SpCas9 和 AsCas12a 被广泛用作人类细胞中的基因组编辑工具。然而，它们相对较大的尺寸对限制货物大小的腺相关病毒 (AAV) 载体的递送造成了限制。来自 Acidibacillus sulfogenics 的 VF Cas12f 型是例外紧凑（422 个氨基酸），并已被用作紧凑的基因组编辑工具。在这里，我们开发了一种方法，结合深度突变扫描和结构知情设计，成功生成两个 AsCas12f... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 22 日：S0092-8674(23)00963-7. doi: 10.1016/j.cell.2023.08.031. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> SpCas9 和 AsCas12a 被广泛用作人类细胞中的基因组编辑工具。然而，它们相对较大的尺寸对限制货物大小的腺相关病毒 (AAV) 载体的递送造成了限制。来自 Acidibacillus sulfogenics 的 VF Cas12f 型是例外紧凑（422 个氨基酸），并已被用作紧凑的基因组编辑工具。在这里，我们开发了一种方法，结合深度突变扫描和结构知情设计，成功生成两个 AsCas12f 活性增强 (enAsCas12f) 变体。值得注意的是， enAsCas12f 在人类细胞中显示出与 SpCas9 和 AsCas12a 变体相当的基因组编辑活性。冷冻电子显微镜 (cryo-EM) 结构显示，突变稳定了二聚体的形成并加强了与核酸的相互作用，从而增强了其 DNA 切割活性。总之，enAsCas12f 变体可以为体内基因治疗提供最小的基因组编辑平台。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37776859/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37776859</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.031>10.1016/j.cell.2023.08.031</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37776859</guid><pubDate> Sat, 30 Sep 2023 06:00:00 -0400</pubDate><dc:creator>日野智博</dc:creator><dc:creator>大村聪</dc:creator><dc:creator>中川亮也</dc:creator><dc:creator>富坚智树</dc:creator><dc:creator>武田悟</dc:creator><dc:creator>平本贵文</dc:creator><dc:creator>田坂聪</dc:creator><dc:creator>平野久里</dc:creator><dc:creator>德山武</dc:creator><dc:creator>鱼崎英树</dc:creator><dc:creator>石黑壮</dc:creator><dc:creator>麦迪娜·卡吉耶娃</dc:creator><dc:creator>山野弘之</dc:creator><dc:creator>尾崎由纪</dc:creator><dc:creator>本冈大辅</dc:creator><dc:creator>森英人</dc:creator><dc:creator>桐田佑平</dc:creator><dc:creator>黄濑义明</dc:creator><dc:creator>伊藤雄</dc:creator><dc:creator>场里明</dc:creator><dc:creator>油谷宏之</dc:creator><dc:creator>谷智望</dc:creator><dc:creator>陶特维达斯·卡维利斯</dc:creator><dc:creator>维尔尼吉斯·西克斯尼斯</dc:creator><dc:creator>大森司</dc:creator><dc:creator>星野敦</dc:creator><dc:creator>努雷木修</dc:creator><dc:date>2023-09-30</dc:date><dc:source>细胞</dc:source><dc:title>基于 AsCas12f 的紧凑型基因组编辑工具，由深度突变扫描和结构分析衍生而来</dc:title><dc:identifier>下午:37776859</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.031</dc:identifier></item><item><title>出生后对 SARS-CoV-2 粘膜和全身免疫的多组学分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37776858/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231001120910&amp;v=2.17.9.post6+86293ac<description>婴儿对感染的免疫力动态仍不清楚。在这里，我们采用多组学方法，通过分析婴儿和幼儿的血液样本，对婴幼儿对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的免疫力进行纵向分析以及每周在感染 Omicron 和非 Omicron 变体之前、期间和之后收集的鼻拭子。感染刺激了强大的抗体滴度，与成人不同，这种滴度在长达 300 天内没有显示出衰减的迹象。婴儿... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 26 日：S0092-8674(23)00978-9. doi: 10.1016/j.cell.2023.08.044. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">婴儿对感染的免疫力动态仍不清楚。在这里，我们采用多组学方法，通过分析婴儿和幼儿的血液样本，对婴幼儿对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的免疫力进行纵向分析以及每周在感染 Omicron 和非 Omicron 变体之前、期间和之后收集的鼻拭子。感染刺激了强大的抗体滴度，与成人不同，该滴度在长达 300 天内没有显示出衰减的迹象。婴儿产生了强大的粘膜免疫反应，其特征是炎症细胞因子、干扰素 (IFN) α 和 T 辅助细胞 (Th) 17 以及中性粒细胞标记物（白细胞介素 [IL]-17、IL-8 和 CXCL1）。血液中的免疫反应的特点是先天激活标记物上调。细胞，没有炎症细胞因子，但有几种趋化因子和 IFNα。后者与通过单细胞多组学测量的骨髓细胞中病毒载量和干扰素刺激基因 (ISG) 的表达相关。总而言之，这些数据提供了免疫的快照在生命的最初几周和几个月内感染。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37776858/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37776858</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.044>10.1016/j.cell.2023.08.044</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37776858</guid><pubDate> Sat, 30 Sep 2023 06:00:00 -0400</pubDate><dc:creator>弗洛里安·威默斯</dc:creator><dc:creator>艾莉森·R·伯勒尔</dc:creator><dc:creator>冯玉鹏</dc:creator><dc:creator>郑洪</dc:creator><dc:creator>帕布·阿鲁纳查兰</dc:creator><dc:creator>胡梦云</dc:creator><dc:creator>萨拉·斯普兰格</dc:creator><dc:creator>林赛·E·尼霍夫</dc:creator><dc:creator>德维亚尼·乔希</dc:creator><dc:creator>米拉·特萨尔</dc:creator><dc:creator>玛扬卡·阿瓦斯提</dc:creator><dc:creator>洛伦扎·贝鲁西</dc:creator><dc:creator>乌萨马·阿什拉夫</dc:creator><dc:creator>桑吉塔·科利</dc:creator><dc:creator>凯瑟琳·康文斯</dc:creator><dc:creator>杨艾米莉</dc:creator><dc:creator>迈克尔·布兰科</dc:creator><dc:creator>凯瑟琳·佩莱格里尼</dc:creator><dc:creator>格雷戈里·萨普</dc:creator><dc:creator>托马斯·哈根</dc:creator><dc:creator>R莎伦·钦特拉贾</dc:creator><dc:creator>陈T阮</dc:creator><dc:creator>阿尔巴·格里福尼</dc:creator><dc:creator>亚历山德罗·塞特</dc:creator><dc:creator>卡里·C·纳多</dc:creator><dc:creator>大卫·B·哈斯拉姆</dc:creator><dc:creator>史蒂文·E·博辛格</dc:creator><dc:creator>延斯·瓦默特</dc:creator><dc:creator>霍尔顿·T·梅克</dc:creator><dc:creator>保罗·尤茨</dc:creator><dc:creator>王泰亚</dc:creator><dc:creator>投降库拉纳</dc:creator><dc:creator>普韦什·卡特里</dc:creator><dc:creator>玛丽·斯塔特</dc:creator><dc:creator>巴厘岛普伦德兰</dc:creator><dc:date>2023-09-30</dc:date><dc:source>细胞</dc:source><dc:title>出生后对 SARS-CoV-2 粘膜和全身免疫的多组学分析</dc:title><dc:identifier>下午：37776858</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.044</dc:identifier></item><item><title> MINOCA 中的性别和种族差异</title><link/>https://pubmed.ncbi.nlm.nih.gov/37775559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231001120910&amp;v=2.17.9.post6+86293ac<description>疑似非梗阻性冠状动脉心肌梗死 (MINOCA) 在过去十年中受到越来越多的关注。考虑到不存在梗阻性冠状动脉的急性心肌梗死机制的异质性，MINOCA 综合征被认为是一种可行的诊断，需要进行诊断。进行诊断性血管造影研究后进行进一步调查，包括冠状动脉磁共振血管造影和功能性血管造影...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 9 月 29 日。doi：10.1038/s41569-023-00927-6。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">疑似非梗阻性冠状动脉心肌梗死 (MINOCA) 在过去十年中受到越来越多的关注。考虑到不存在梗阻性冠状动脉的急性心肌梗死机制的异质性，MINOCA 综合征被认为是一种可行的诊断，需要进行诊断。尽管一度被认为是一种罕见且低风险的心肌梗死形式，但最近的数据表明，MINOCA 的预后并不像以前假设的那样良性。然而，尽管人们对该病的认识不断提高，但关于 MINOCA 的诊断、风险分层和治疗仍然存在许多问题。女性似乎同样容易患 MINOCA，但关于该疾病的性别差异的研究很少。这些因素可能解释了 MINOCA 观察到的患病率或潜在病理生理机制的差异，但数据也很少。因此，在本综述中，我们提供了有关临床特征中性别特异性和种族特异性差异的最新证据的更新， MINOCA 的病理生理机制、治疗和预后。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37775559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37775559</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00927-6>10.1038/s41569-023-00927-6</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37775559</guid><pubDate> Fri, 29 Sep 2023 06:00:00 -0400</pubDate><dc:creator>萨雷娜·拉</dc:creator><dc:creator>约翰·贝尔特拉姆</dc:creator><dc:creator>罗莎娜·塔维拉</dc:creator><dc:date>2023-09-29</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>MINOCA 中的性别和种族差异</dc:title><dc:identifier>下午:37775559</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00927-6</dc:identifier></item><item><title>合成 Par 极性诱导未极化哺乳动物细胞的细胞骨架不对称</title><link/>https://pubmed.ncbi.nlm.nih.gov/37774705/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231001120910&amp;v=2.17.9.post6+86293ac<description>极化细胞依赖于极化的细胞骨架来发挥作用。然而，皮质极性线索如何诱导细胞骨架极化仍然是难以捉摸的。在这里，我们利用最近建立的设计的二维蛋白质阵列来异位改造几乎任何感兴趣的蛋白质在各种细胞类型的有丝分裂过程中的皮质极性。这使得能够直接操纵极性信号传导并识别足以细胞骨架极化的皮质线索。使用这种测定，我们... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 20 日：S0092-8674(23)00968-6. doi: 10.1016/j.cell.2023.08.034. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">极化细胞依赖于极化的细胞骨架来发挥作用。然而，皮质极性线索如何诱导细胞骨架极化仍然是难以捉摸的。在这里，我们利用最近建立的设计的二维蛋白质阵列来异位改造几乎任何感兴趣的蛋白质在各种细胞类型的有丝分裂过程中的皮质极性这使得能够直接操纵极性信号传导并识别足以进行细胞骨架极化的皮质线索。使用这种测定，我们剖析了 Par 复合体途径的逻辑，Par 复合体途径是不对称细胞分裂期间细胞骨架极性的关键调节因子。我们表明，任何 Par 复合体亚基都足以触发复合体组装，并且复合体组装的主要动力学障碍是 Par6 自抑制的缓解。此外，我们发现诱导皮质 Par 复合体极性会诱导非极化哺乳动物细胞中不对称细胞分裂的两个标志：纺锤体方向，通过 Par3 和中心纺锤体不对称发生，具体取决于 aPKC 活性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37774705/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37774705</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.034>10.1016/j.cell.2023.08.034</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37774705</guid><pubDate> Fri, 29 Sep 2023 06:00:00 -0400</pubDate><dc:creator>约瑟夫·沃森</dc:creator><dc:creator>拉拉·K·克鲁格</dc:creator><dc:creator>阿里尔·J·本-萨森</dc:creator><dc:creator>艾丽丝·比特斯顿</dc:creator><dc:creator>玛尔塔·N·沙巴齐</dc:creator><dc:creator>维森特·何塞·普拉内勒斯-埃雷罗</dc:creator><dc:creator>约瑟夫·E·钱伯斯</dc:creator><dc:creator>詹姆斯·D·曼顿</dc:creator><dc:creator>大卫·贝克</dc:creator><dc:creator>伊曼纽尔交付</dc:creator><dc:date>2023-09-29</dc:date><dc:source>细胞</dc:source><dc:title>合成 Par 极性诱导未极化哺乳动物细胞的细胞骨架不对称</dc:title><dc:identifier>下午:37774705</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.034</dc:identifier></item><item><title>广泛分布的基因簇补偿了原始人类尿酸酶的损失</title><link/>https://pubmed.ncbi.nlm.nih.gov/37774682/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231001120910&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 9 月 28 日；186(20):4472-4473.doi:10.1016/j.cell.2023.08.036。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37774682/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37774682</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.036>10.1016/j.cell.2023.08.036</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37774682</guid><pubDate> Fri, 29 Sep 2023 06:00:00 -0400</pubDate><dc:creator>刘媛媛</dc:creator><dc:creator>J·布莱斯·贾曼</dc:creator><dc:creator>日元S低</dc:creator><dc:creator>汉娜·E·奥古斯丁</dc:creator><dc:creator>史蒂文·黄</dc:creator><dc:creator>陈浩清</dc:creator><dc:creator>玛丽·E·笛福</dc:creator><dc:creator>关场和真</dc:creator><dc:creator>侯碧慧</dc:creator><dc:creator>孟宪东</dc:creator><dc:creator>艾莉森·M·威克利</dc:creator><dc:creator>阿什利·V·卡布雷拉</dc:creator><dc:creator>周志伟</dc:creator><dc:creator>吉尔斯·范韦泽尔</dc:creator><dc:creator>马尼克斯·H·梅德玛</dc:creator><dc:creator>卡利亚尼·加内桑</dc:creator><dc:creator>包正伦</dc:creator><dc:creator>索拉巴·贡巴尔</dc:creator><dc:creator>迪伦·多德</dc:creator><dc:date>2023-09-29</dc:date><dc:source>细胞</dc:source><dc:title>广泛分布的基因簇补偿了原始人类尿酸酶的损失</dc:title><dc:identifier>下午:37774682</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.036</dc:identifier></item><item><title>人类皮质的早期阿尔茨海默病病理涉及短暂的细胞状态</title><link/>https://pubmed.ncbi.nlm.nih.gov/37774681/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231001120910&amp;v=2.17.9.post6+86293ac<description>阿尔茨海默氏病 (AD) 潜在的细胞扰动主要在人类死后样本和模型生物中进行研究。在这里，我们从具有不同程度 AD 病理的活体个体的一组罕见的皮质活检中生成了单核图谱。接下来，我们进行了系统性研究跨疾病和跨物种综合分析，以确定一组特定于早期 AD 病理学的细胞状态。这些变化——我们称之为早期皮质淀粉样蛋白…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 9 月 28 日；186(20):4438-4453.e23.doi:10.1016/j.cell.2023.08.005。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">阿尔茨海默氏病 (AD) 潜在的细胞扰动主要在人类死后样本和模型生物中进行研究。在这里，我们从具有不同程度 AD 病理的活体个体的一组罕见的皮质活检中生成了单核图谱。接下来，我们进行了系统性研究跨疾病和跨物种综合分析，以确定一组特定于早期 AD 病理学的细胞状态。这些变化（我们称之为早期皮质淀粉样反应）在神经元中很突出，因此我们确定了一种过渡性过度活跃状态在兴奋性神经元丧失之前，我们通过独立活检标本的急性切片生理学证实了这一点。随着 AD 病理的增加，小胶质细胞过度表达的神经炎症相关过程也随之扩大。最后，少突胶质细胞和锥体神经元都上调了与 β-淀粉样蛋白产生和加工相关的基因。我们的综合分析为 AD 发病机制早期的回路功能障碍、神经炎症和淀粉样蛋白产生提供了一个组织框架。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37774681/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37774681</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.005>10.1016/j.cell.2023.08.005</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37774681</guid><pubDate> Fri, 29 Sep 2023 06:00:00 -0400</pubDate><dc:creator>瓦希德·加泽斯塔尼</dc:creator><dc:creator>图沙尔·卡马斯</dc:creator><dc:creator>纳伊姆·纳达夫</dc:creator><dc:creator>安东尼奥·杜加利斯</dc:creator><dc:creator>S·J·伯里斯</dc:creator><dc:creator>布伦丹·鲁尼</dc:creator><dc:creator>安蒂·琼卡里</dc:creator><dc:creator>查尔斯·范德堡</dc:creator><dc:creator>安西·佩尔科宁</dc:creator><dc:creator>米雷亚·戈麦斯-布迪亚</dc:creator><dc:creator>内利-努拉·瓦利迈基</dc:creator><dc:creator>托马斯·劳拉玛</dc:creator><dc:creator>玛蒂娜·瑟林</dc:creator><dc:creator>安妮·M·科伊维斯托</dc:creator><dc:creator>马修·特格迈尔</dc:creator><dc:creator>桑那佳萨胜乐卡</dc:creator><dc:creator>阿卜杜勒拉乌夫 阿卜杜勒拉乌夫</dc:creator><dc:creator>塞缪尔·E·马什</dc:creator><dc:creator>米科·希尔图宁</dc:creator><dc:creator>拉尔达·内梅</dc:creator><dc:creator>塔里娅·马尔姆</dc:creator><dc:creator>贝丝·史蒂文斯</dc:creator><dc:creator>维尔·莱诺宁</dc:creator><dc:creator>埃文·Z·马科斯科</dc:creator><dc:date>2023-09-29</dc:date><dc:source>细胞</dc:source><dc:title>人类皮质的早期阿尔茨海默病病理涉及短暂的细胞状态</dc:title><dc:identifier>下午:37774681</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.005</dc:identifier></item><item><title>阿尔茨海默病的表观基因组解剖查明因果变异并揭示表观基因组侵蚀</title><link/>https://pubmed.ncbi.nlm.nih.gov/37774680/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231001120910&amp;v=2.17.9.post6+86293ac<description>最近的工作已经确定了数十个与阿尔茨海默氏病 (AD) 风险相关的非编码位点，但对它们的机制和 AD 转录调控电路知之甚少。在这里，我们对 92 名患有或不患有阿尔茨海默病的个体前额皮质的 850,000 个细胞核的表观基因组和转录组景观进行了分析。 AD 构建大脑调节组图谱，包括表观基因组图谱、转录调节因子、共可访问性模块以及以细胞类型特异性方式进行的峰到基因链接。我们... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 9 月 28 日；186(20):4422-4437.e21.doi:10.1016/j.cell.2023.08.040。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">最近的工作已经确定了数十个与阿尔茨海默氏病 (AD) 风险相关的非编码位点，但对它们的机制和 AD 转录调控电路知之甚少。在这里，我们对 92 名患有或不患有阿尔茨海默病的个体前额皮质的 850,000 个细胞核的表观基因组和转录组景观进行了分析。 AD 构建大脑调节组图谱，包括表观基因组图谱、转录调节因子、共可访问性模块以及以细胞类型特异性方式进行的峰与基因链接。我们开发了多模式整合方法并使用峰检测调节模块与基因的关联。我们显示 AD 风险位点在小胶质细胞增强子和特定 TF 中富集，包括 SPI1、ELF2 和 RUNX1。我们检测到 9,628 个细胞类型特异性 ATAC-QTL 位点，我们将其与峰到基因整合在一起优先考虑 AD 变异调节回路的链接。我们报告了 AD 晚期神经胶质细胞和 AD 早期神经元调节模块的可及性差异。引人注目的是，晚期 AD 大脑表现出全局表观基因组失调，表明表观基因组侵蚀和细胞身份丢失。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37774680/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37774680</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.040>10.1016/j.cell.2023.08.040</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37774680</guid><pubDate> Fri, 29 Sep 2023 06:00:00 -0400</pubDate><dc:creator>熊旭申</dc:creator><dc:creator>本杰明·詹姆斯</dc:creator><dc:creator>卡尔斯·A·博瓦</dc:creator><dc:creator>永进P公园</dc:creator><dc:creator>基里亚基·加拉尼</dc:creator><dc:creator>马修斯·B·维克多</dc:creator><dc:creator>孙娜</dc:creator><dc:creator>侯雷</dc:creator><dc:creator>何立伦</dc:creator><dc:creator>胡里奥·曼特罗</dc:creator><dc:creator>艾内·尼·斯坎内尔</dc:creator><dc:creator>毗湿奴迪利普</dc:creator><dc:creator>董伟秀</dc:creator><dc:creator>汉斯鲁迪·马蒂斯</dc:creator><dc:creator>大卫·贝内特</dc:creator><dc:creator>蔡立惠</dc:creator><dc:creator>马诺利斯·凯利斯</dc:creator><dc:date>2023-09-29</dc:date><dc:source>细胞</dc:source><dc:title>阿尔茨海默病的表观基因组解剖查明因果变异并揭示表观基因组侵蚀</dc:title><dc:identifier>下午:37774680</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.040</dc:identifier></item><item><title>神经元 DNA 双链断裂导致神经退行性疾病中的基因组结构变异和 3D 基因组破坏</title><link/>https://pubmed.ncbi.nlm.nih.gov/37774679/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231001120910&amp;v=2.17.9.post6+86293ac<description>神经元中持续的 DNA 双链断裂 (DSB) 是包括阿尔茨海默病 (AD) 在内的神经退行性疾病的早期病理标志，有可能破坏基因组完整性。我们在人类死后前额皮质样本中使用单核 RNA 测序，发现AD 中的兴奋性神经元富含体细胞嵌合基因融合。基因融合在具有 DNA 损伤修复和衰老基因特征的兴奋性神经元中尤其丰富。此外，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 9 月 28 日；186(20):4404-4421.e20.doi:10.1016/j.cell.2023.08.038。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">神经元中持续的 DNA 双链断裂 (DSB) 是包括阿尔茨海默病 (AD) 在内的神经退行性疾病的早期病理标志，有可能破坏基因组完整性。我们在人类死后前额皮质样本中使用单核 RNA 测序，发现AD 中的兴奋性神经元富含体细胞嵌合基因融合。基因融合在具有 DNA 损伤修复和衰老基因特征的兴奋性神经元中尤其丰富。此外，体细胞基因组结构变异和基因融合在 CK 中负载 DSB 的神经元中丰富-p25 神经变性小鼠模型。富含 DSB 的神经元的粘连蛋白水平也升高，同时 3D 基因组组织的渐进性多尺度破坏与突触、神经元发育和组蛋白基因的转录变化相一致。总体而言，这项研究证明了基因组的破坏神经元中 DSB 的稳定性和 3D 基因组组织作为神经退行性疾病进展的病理步骤。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37774679/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37774679</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.038>10.1016/j.cell.2023.08.038</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37774679</guid><pubDate> Fri, 29 Sep 2023 06:00:00 -0400</pubDate><dc:creator>毗湿奴迪利普</dc:creator><dc:creator>卡尔斯·A·博瓦</dc:creator><dc:creator>汉斯鲁迪·马蒂斯</dc:creator><dc:creator>阿萨夫·马可</dc:creator><dc:creator>格温妮丝·M·韦尔奇</dc:creator><dc:creator>希鲁伊·梅哈雷纳</dc:creator><dc:creator>安珍妮·卢恩</dc:creator><dc:creator>里蒂卡·杰洛卡</dc:creator><dc:creator>彭祝玉</dc:creator><dc:creator>大卫·贝内特</dc:creator><dc:creator>马诺利斯·凯利斯</dc:creator><dc:creator>蔡立惠</dc:creator><dc:date>2023-09-29</dc:date><dc:source>细胞</dc:source><dc:title>神经元 DNA 双链断裂导致神经退行性疾病中的基因组结构变异和 3D 基因组破坏</dc:title><dc:identifier>下午:37774679</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.038</dc:identifier></item><item><title>阿尔茨海默病进展中的人类小胶质细胞状态动态</title><link/>https://pubmed.ncbi.nlm.nih.gov/37774678/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231001120910&amp;v=2.17.9.post6+86293ac<description>改变的小胶质细胞状态会影响神经炎症、神经退行性疾病和疾病，但人们对此仍知之甚少。在这里，我们报告了 443 名人类受试者和不同阿尔茨海默病 (AD) 病理表型的 194,000 个单核小胶质细胞转录组和表观基因组。我们注释了 12 种小胶质细胞转录状态，包括 AD -稳态失调、炎症和脂质加工状态。我们鉴定了 1,542 个 AD 差异表达基因，包括…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 9 月 28 日；186(20):4386-4403.e29.doi:10.1016/j.cell.2023.08.037。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">改变的小胶质细胞状态会影响神经炎症、神经退行性疾病和疾病，但人们对此仍知之甚少。在这里，我们报告了 443 名人类受试者和不同阿尔茨海默病 (AD) 病理表型的 194,000 个单核小胶质细胞转录组和表观基因组。我们注释了 12 种小胶质细胞转录状态，包括 AD -稳态失调、炎症和脂质加工状态。我们鉴定了 1,542 个 AD 差异表达基因，包括小胶质细胞状态特异性和疾病阶段特异性改变。通过整合表观基因组、转录组和基序信息，我们推断上游小胶质细胞状态、基因调控网络、增强子基因链接和转录因子驱动的小胶质细胞状态转变的调节因子。我们证明，我们预测的稳态激活因子的异位表达可诱导人 iPSC 衍生的小胶质细胞样细胞的稳态特征，同时抑制炎症激活剂可以阻止炎症进展。最后，我们查明了小胶质细胞状态中 AD 风险基因的表达以及 AD 进展过程中 AD 风险基因及其调节因子的差异表达。总的来说，我们提供了小胶质细胞状态的基础见解，包括以前所未有的分辨率进行状态特异性和 AD 阶段特异性的小胶质细胞改变。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37774678/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37774678</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.037>10.1016/j.cell.2023.08.037</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37774678</guid><pubDate> Fri, 29 Sep 2023 06:00:00 -0400</pubDate><dc:creator>孙娜</dc:creator><dc:creator>马修斯·B·维克多</dc:creator><dc:creator>永进P公园</dc:creator><dc:creator>熊旭申</dc:creator><dc:creator>艾内·尼·斯坎内尔</dc:creator><dc:creator>诺埃尔·利里</dc:creator><dc:creator>夏妮亚·普洛斯珀</dc:creator><dc:creator>苏詹亚·维斯瓦纳坦</dc:creator><dc:creator>索奇特尔·卢纳</dc:creator><dc:creator>卡尔斯·A·博瓦</dc:creator><dc:creator>本杰明·詹姆斯</dc:creator><dc:creator>谷川洋介</dc:creator><dc:creator>基里亚基·加拉尼</dc:creator><dc:creator>汉斯鲁迪·马蒂斯</dc:creator><dc:creator>江雪桥</dc:creator><dc:creator>吴艾莎</dc:creator><dc:creator>大卫·贝内特</dc:creator><dc:creator>蔡立惠</dc:creator><dc:creator>马诺利斯·凯利斯</dc:creator><dc:date>2023-09-29</dc:date><dc:source>细胞</dc:source><dc:title>阿尔茨海默病进展中的人类小胶质细胞状态动态</dc:title><dc:identifier>下午：37774678</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.037</dc:identifier></item><item><title>单细胞图谱揭示了高认知功能、痴呆和阿尔茨海默氏病病理恢复力的相关性</title><link/>https://pubmed.ncbi.nlm.nih.gov/37774677/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231001120910&amp;v=2.17.9.post6+86293ac<description>阿尔茨海默病 (AD) 是全世界痴呆症最常见的原因，但认知障碍背后的分子和细胞机制仍知之甚少。为了解决这个问题，我们生成了老年人前额叶皮层的单细胞转录组图谱，涵盖了 230 万个细胞427 名患有不同程度 AD 病理学和认知障碍的个体的死后人脑样本。我们的分析发现了与 AD 病理学相关的改变... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 9 月 28 日；186(20):4365-4385.e27.doi:10.1016/j.cell.2023.08.039。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">阿尔茨海默病 (AD) 是全世界痴呆症最常见的原因，但认知障碍背后的分子和细胞机制仍知之甚少。为了解决这个问题，我们生成了老年人前额叶皮层的单细胞转录组图谱，涵盖了 230 万个细胞对 427 名患有不同程度的 AD 病理学和认知障碍的个体进行死后人脑样本。我们的分析确定了兴奋性神经元亚型之间共有的与 AD 病理学相关的改变，揭示了兴奋性神经元和少突胶质细胞，并发现了与高认知功能、痴呆和 AD 病理恢复力相关的基因和通路。此外，我们还选择性地鉴定了 AD 中缺失的易受影响的生长抑素抑制性神经元亚型，发现了两组不同的抑制性神经元，它们在保留了 AD 功能的个体中更为丰富。晚年的高认知功能，并揭示了抑制性神经元与 AD 病理恢复之间的联系。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37774677/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37774677</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.039>10.1016/j.cell.2023.08.039</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37774677</guid><pubDate> Fri, 29 Sep 2023 06:00:00 -0400</pubDate><dc:creator>汉斯鲁迪·马蒂斯</dc:creator><dc:creator>彭祝玉</dc:creator><dc:creator>卡尔斯·A·博瓦</dc:creator><dc:creator>马修斯·B·维克多</dc:creator><dc:creator>诺埃尔·利里</dc:creator><dc:creator>苏达加尔·巴布</dc:creator><dc:creator>加达·阿卜杜勒哈迪</dc:creator><dc:creator>江雪桥</dc:creator><dc:creator>吴艾莎</dc:creator><dc:creator>基米亚·加法里</dc:creator><dc:creator>亚历山大·K·库尼斯基</dc:creator><dc:creator>胡里奥·曼特罗</dc:creator><dc:creator>基里亚基·加拉尼</dc:creator><dc:creator>万希卡·N·洛希亚</dc:creator><dc:creator>加布里埃尔·E·福蒂尔</dc:creator><dc:creator>亚斯敏·洛特菲</dc:creator><dc:creator>贾森·艾维</dc:creator><dc:creator>汉娜·P·布朗</dc:creator><dc:creator>帕特尔</dc:creator><dc:creator>内哈·查克拉博蒂</dc:creator><dc:creator>雅各布·博韦</dc:creator><dc:creator>伊丽莎白·J·伊姆霍夫</dc:creator><dc:creator>卡梅伦·F·基勒</dc:creator><dc:creator>马伦·麦克切斯尼</dc:creator><dc:creator>海沙尔·H·帕特尔</dc:creator><dc:creator>萨希尔·P·帕特尔</dc:creator><dc:creator>梅根·泰</dc:creator><dc:creator>大卫·贝内特</dc:creator><dc:creator>马诺利斯·凯利斯</dc:creator><dc:creator>蔡立惠</dc:creator><dc:date>2023-09-29</dc:date><dc:source>细胞</dc:source><dc:title>单细胞图谱揭示了高认知功能、痴呆和阿尔茨海默氏病病理恢复力的相关性</dc:title><dc:identifier>下午：37774677</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.039</dc:identifier></item><item><title>跟踪人类和小鼠大脑中细胞类型特异性的时间动态</title><link/>https://pubmed.ncbi.nlm.nih.gov/37774676/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231001120910&amp;v=2.17.9.post6+86293ac<description>祖细胞对于维持机体稳态至关重要，但它们在衰老大脑中的多样性和动态仍未得到充分探索。我们引入了 TrackerSci，这是一种单细胞基因组方法，结合了新生细胞标记和组合索引来表征增殖祖细胞的转录组和染色质景观使用 TrackerSci，我们研究了不同年龄小鼠大脑中以及阿尔茨海默病小鼠模型中新生细胞的动态…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 9 月 28 日；186(20):4345-4364.e24.doi:10.1016/j.cell.2023.08.042。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">祖细胞对于维持机体稳态至关重要，但它们在衰老大脑中的多样性和动态仍未得到充分探索。我们引入了 TrackerSci，这是一种单细胞基因组方法，结合了新生细胞标记和组合索引来表征增殖祖细胞的转录组和染色质景观体内。使用 TrackerSci，我们研究了不同年龄的小鼠大脑和阿尔茨海默病小鼠模型中新生细胞的动态。我们的数据集揭示了大脑中不同的祖细胞类型及其表观遗传特征。我们进一步量化了与衰老相关的变化细胞类型特异性增殖和分化，并破译了相关的分子程序。将我们的研究扩展到衰老人脑中的祖细胞，我们发现了跨物种的保守遗传特征，并精确定位了区域特异性细胞动力学，例如少突胶质细胞生成减少我们预计 TrackerSci 将广泛应用于揭示不同系统中细胞类型特异性的时间动态。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37774676/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37774676</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.042>10.1016/j.cell.2023.08.042</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37774676</guid><pubDate> Fri, 29 Sep 2023 06:00:00 -0400</pubDate><dc:creator>子育路</dc:creator><dc:creator>张梅丽莎</dc:creator><dc:creator>李子豪</dc:creator><dc:creator>安德拉斯·西拉基</dc:creator><dc:creator>索尼娅·安德森</dc:creator><dc:creator>张泽浩</dc:creator><dc:creator>徐子涵</dc:creator><dc:creator>蒋伟荣</dc:creator><dc:creator>葛少宇</dc:creator><dc:creator>彼得·T·纳尔逊</dc:creator><dc:creator>周伟</dc:creator><dc:creator>曹俊跃</dc:creator><dc:date>2023-09-29</dc:date><dc:source>细胞</dc:source><dc:title>跟踪人类和小鼠大脑中细胞类型特异性的时间动态</dc:title><dc:identifier>下午：37774676</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.042</dc:identifier></item><item><title>公元2023年奥德赛：单细胞的故事</title><link/>https://pubmed.ncbi.nlm.nih.gov/37774675/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231001120910&amp;v=2.17.9.post6+86293ac<description>使用具有明确临床阶段的大型队列来解读阿尔茨海默病 (AD) 的细胞变化对于了解 AD 进展的不同轨迹至关重要。在本期《Cell》中，五项研究利用了单核 RNA 测序 (snRNA-seq) 的力量，单核 ATAC 测序 (snATAC-seq) 规模空前，揭示了 AD 发病机制进展中细胞类型特异性机制的令人兴奋的见解。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 9 月 28 日；186(20):4257-4259.doi:10.1016/j.cell.2023.09.001。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">使用具有明确临床阶段的大型队列来解读阿尔茨海默病 (AD) 的细胞变化对于了解 AD 进展的不同轨迹至关重要。在本期《Cell》中，五项研究利用了单核 RNA 测序 (snRNA-seq) 的力量，单核 ATAC 测序 (snATAC-seq) 规模空前，揭示了 AD 发病机制进展中细胞类型特异性机制的令人兴奋的见解。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37774675/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37774675</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.09.001>10.1016/j.cell.2023.09.001</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37774675</guid><pubDate> Fri, 29 Sep 2023 06:00:00 -0400</pubDate><dc:creator>罗文杰</dc:creator><dc:creator>曲文辉</dc:creator><dc:creator>李干</dc:creator><dc:date>2023-09-29</dc:date><dc:source>细胞</dc:source><dc:title>公元2023年奥德赛：单细胞的故事</dc:title><dc:identifier>下午:37774675</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.09.001</dc:identifier></item><item><title>印度女性心脏病专家从“TAWA”到“TAVI-经导管主动脉瓣植入术”的历程</title><link/>https://pubmed.ncbi.nlm.nih.gov/37774363/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231001120910&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 29:ehad652.doi: 10.1093/eurheartj/ehad652. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37774363/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37774363</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad652>10.1093/eurheartj/ehad652</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37774363</guid><pubDate> Fri, 29 Sep 2023 06:00:00 -0400</pubDate><dc:creator>希巴·塔卡·查布拉</dc:creator><dc:creator>阿斯塔·塔卡</dc:creator><dc:creator>拉杰什·昌德·艾莉亚</dc:creator><dc:date>2023-09-29</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>印度女性心脏病专家从“TAWA”到“TAVI-经导管主动脉瓣植入术”的历程</dc:title><dc:identifier>下午：37774363</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad652</dc:identifier></item><item><title>对既往做过搭桥手术的患者进行侵入性冠状动脉造影前的计算机断层扫描心脏血管造影：BYPASS-CTCA 试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37772419/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231001120910&amp;v=2.17.9.post6+86293ac<description>结论：对于既往接受冠状动脉旁路移植术的患者，ICA前CTCA可减少手术时间，减少对比剂肾病，提高患者满意度，该组患者应考虑ICA前CTCA。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 29 日。doi：10.1161/CIRCULATIONAHA.123.064465。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：既往接受过冠状动脉搭桥术的患者通常需要进行侵入性冠状动脉造影（ICA），但对于这些患者来说，该过程在技术上更具挑战性，且并发症风险较高。观察性研究表明，计算机断层扫描心脏血管造影（CTCA）可能促进该组中的 ICA，但这尚未在随机对照试验中进行测试。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：本研究是一项单中心、开放标签随机对照试验，评估辅助 CTCA 对既往接受过冠状动脉旁路移植术并转诊至 ICA 的患者的益处。患者按照 1:1 的比例随机分配，接受 ICA 之前接受 CTCA 或单独接受 ICA。共同主要终点是 ICA 的手术持续时间（定义为获得血管通路的局部麻醉与拔除最后一根导管之间的时间间隔）、使用经过验证的问卷进行 ICA 后的患者满意度以及造影剂肾病的发生率。使用线性回归计算手术持续时间和患者满意度评分；使用逻辑回归分析对比剂诱发的肾病。我们应用了 Bonferroni 校正， <i>P</i> &lt;0.017 被认为是显着的，置信区间为 98.33%。次要终点包括手术并发症的发生率和 1年主要不良心脏事件。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Over 3 years, 688 patients were randomized with a median follow-up of 1.0 years. The mean age was 69.8±10.4 years, 108 (15.7%) were women, 402 (58.4%) were White, and there was a high burden of comorbidity (85.3% hypertension and 53.8% diabetes). The median time from coronary artery bypass grafting to angiography was 12.0 years, and there were a median of 3 (interquartile range, 2 to 3) grafts per participant. Procedure duration of the ICA was significantly shorter in the CTCA+ICA group (CTCA+ICA, 18.6±9.5 minutes versus ICA alone, 39.5±16.9 minutes [98.33% CI, -23.5 to -18.4]; <i>P</i> &lt;0.001), alongside improved mean ICA satisfaction scores (1=very good to 5=very poor; -1.1 difference [98.33% CI, -1.2 to -0.9]; <i>P</i> &lt;0.001), and reduced incidence of contrast-induced nephropathy (3.4% versus 27.9%; odds ratio, 0.09 [98.33% CI, 0.04-0.2]; <i>P</i> &lt;0.001). Procedural complications (2.3% versus 10.8%; odds ratio, 0.2 [95% CI, 0.1-0.4]; <i>P</i> &lt;0.001) and 1-year major adverse cardiac events (16.0% versus 29.4%; hazard ratio, 0.4 [95% CI, 0.3-0.6]; <i>P</i> &lt;0.001) were also lower in the CTCA+ICA group. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: For patients with previous coronary artery bypass grafting, CTCA before ICA leads to reductions in procedure time and contrast-induced nephropathy, with improved patient satisfaction. CTCA before ICA should be considered in this group of patients. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> REGISTRATION: URL: https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CLINICALTRIALS: gov; Unique identifier: NCT03736018.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37772419/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37772419</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064465>10.1161/CIRCULATIONAHA.123.064465</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37772419</guid><pubDate> Fri, 29 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Daniel A Jones</dc:creator><dc:creator> Anne-Marie Beirne</dc:creator><dc:creator> Matthew Kelham</dc:creator><dc:creator> Krishnaraj S Rathod</dc:creator><dc:creator> Mervyn Andiapen</dc:creator><dc:creator> Lucinda Wynne</dc:creator><dc:creator> Thomas Godec</dc:creator><dc:creator> Nasim Forooghi</dc:creator><dc:creator> Rohini Ramaseshan</dc:creator><dc:creator> James C Moon</dc:creator><dc:creator> Ceri Davies</dc:creator><dc:creator> Christos V Bourantas</dc:creator><dc:creator> Andreas Baumbach</dc:creator><dc:creator> Charlotte Manisty</dc:creator><dc:creator> Andrew Wragg</dc:creator><dc:creator> Amrita Ahluwalia</dc:creator><dc:creator> Francesca Pugliese</dc:creator><dc:creator> Anthony Mathur</dc:creator><dc:creator> BYPASS-CTCA Trial Committees and Investigators</dc:creator><dc:date> 2023-09-29</dc:date><dc:source> Circulation</dc:source><dc:title> Computed Tomography Cardiac Angiography Before Invasive Coronary Angiography in Patients With Previous Bypass Surgery: The BYPASS-CTCA Trial</dc:title><dc:identifier> pmid:37772419</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.064465</dc:identifier></item><item><title> An Anterior Second Heart Field Enhancer Regulates the Gene Regulatory Network of the Cardiac Outflow Tract</title><link/> https://pubmed.ncbi.nlm.nih.gov/37772400/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231001120910&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Our results using human and mouse models reveal an essential gene regulatory network of the OFT that requires an anterior second heart field enhancer to link GATA6 with NKX2-5-dependent rotation and septation gene programs. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 29. doi: 10.1161/CIRCULATIONAHA.123.065700. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Conotruncal defects due to developmental abnormalities of the outflow tract (OFT) are an important cause of cyanotic congenital heart disease. Dysregulation of transcriptional programs tuned by NKX2-5, GATA6, and TBX1 have been implicated in abnormal OFT morphogenesis. However, there remains no consensus on how these transcriptional programs function in a unified gene regulatory network within the OFT. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We generated mice harboring a 226-nucleotide deletion of a highly conserved cardiac enhancer containing 2 GATA-binding sites located ≈9.4 kb upstream of the transcriptional start site of <i>Nkx2-5</i> ( <i>Nkx2-5</i> <sup><i>∆enh</i></sup> ) using CRISPR-Cas9 gene editing and assessed phenotypes. Cardiac defects in <i>Nkx2-5</i> <sup><i>∆enh/∆enh</i></sup> mice were structurally characterized using histology and scanning electron micrography, and physiologically assessed using electrocardiography, echocardiography, and optical mapping. Transcriptome analyses were performed using RNA sequencing and single-cell RNA sequencing data sets. Endogenous GATA6 interaction with and activity on the <i>NKX2-5</i> enhancer was studied using chromatin immunoprecipitation sequencing and transposase-accessible chromatin sequencing in human induced pluripotent stem cell-derived cardiomyocytes. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: <i>Nkx2-5</i> <sup><i>∆enh/∆enh</i></sup> mice recapitulated cyanotic conotruncal defects seen in patients with <i>NKX2-5, GATA6,</i> and <i>TBX1</i> mutations. <i>Nkx2-5</i> <sup><i>∆enh/∆enh</i></sup> mice also exhibited defects in right Purkinje fiber network formation, resulting in right bundle-branch block. Enhancer deletion reduced embryonic <i>Nkx2-5</i> expression selectively in the right ventricle and OFT of mutant hearts, indicating that enhancer activity is localized to the anterior second heart field. Transcriptional profiling of the mutant OFT revealed downregulation of important genes involved in OFT rotation and septation, such as <i>Tbx1, Pitx2,</i> and <i>Sema3c</i> . Endogenous GATA6 interacted with the highly conserved enhancer in human induced pluripotent stem cell-derived cardiomyocytes and in wild-type mouse hearts. We found critical dose dependency of cardiac enhancer accessibility on GATA6 gene dosage in human induced pluripotent stem cell-derived cardiomyocytes. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Our results using human and mouse models reveal an essential gene regulatory network of the OFT that requires an anterior second heart field enhancer to link GATA6 with NKX2-5-dependent rotation and septation gene programs.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37772400/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37772400</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065700>10.1161/CIRCULATIONAHA.123.065700</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37772400</guid><pubDate> Fri, 29 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Naoko Yamaguchi</dc:creator><dc:creator> Ernest W Chang</dc:creator><dc:creator> Ziyan Lin</dc:creator><dc:creator> Akshay Shekhar</dc:creator><dc:creator> Lei Bu</dc:creator><dc:creator> Alireza Khodadadi-Jamayran</dc:creator><dc:creator> Aristotelis Tsirigos</dc:creator><dc:creator> Yiyun Cen</dc:creator><dc:creator> Colin KL Phoon</dc:creator><dc:creator> Ivan P Moskowitz</dc:creator><dc:creator> David S Park</dc:creator><dc:date> 2023-09-29</dc:date><dc:source> Circulation</dc:source><dc:title> An Anterior Second Heart Field Enhancer Regulates the Gene Regulatory Network of the Cardiac Outflow Tract</dc:title><dc:identifier> pmid:37772400</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065700</dc:identifier></item><item><title> The ESC Working Group on Coronary Pathophysiology and Microcirculation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37772387/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231001120910&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 29:ehad650. doi: 10.1093/eurheartj/ehad650. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37772387/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37772387</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad650>10.1093/eurheartj/ehad650</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37772387</guid><pubDate> Fri, 29 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Teresa Padro</dc:creator><dc:creator> Edina Cenko</dc:creator><dc:creator> Dimitris Tousoulis</dc:creator><dc:date> 2023-09-29</dc:date><dc:source> European heart journal</dc:source><dc:title> The ESC Working Group on Coronary Pathophysiology and Microcirculation</dc:title><dc:identifier> pmid:37772387</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad650</dc:identifier></item><item><title> Preclinicaltrials.eu: prospective registration of animal studies</title><link/> https://pubmed.ncbi.nlm.nih.gov/37769667/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231001120910&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 28:ehad623. doi: 10.1093/eurheartj/ehad623. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37769667/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37769667</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad623>10.1093/eurheartj/ehad623</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37769667</guid><pubDate> Thu, 28 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Julia ML Menon</dc:creator><dc:creator> Mira van der Naald</dc:creator><dc:creator> Steven AJ Chamuleau</dc:creator><dc:creator> Dirk J Duncker</dc:creator><dc:date> 2023-09-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Preclinicaltrials.eu: prospective registration of animal studies</dc:title><dc:identifier> pmid:37769667</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad623</dc:identifier></item><item><title> Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine</title><link/> https://pubmed.ncbi.nlm.nih.gov/37769658/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231001120910&amp;v=2.17.9.post6+86293ac<description> SARS-CoV-2 primary strain-based vaccination exerts a protective effect against Omicron variants-initiated infection, symptom occurrence, and disease severity in a booster-dependent manner. Yet, the underlying mechanisms remain unclear. During the 2022 Omicron outbreak in Shanghai, we enrolled 122 infected adults and 50 uninfected controls who had been unvaccinated or vaccinated with two or three doses of COVID-19 inactive vaccines and performed integrative analysis of 41-plex CyTOF, RNA-seq, and... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 20:S0092-8674(23)00964-9. doi: 10.1016/j.cell.2023.08.033. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> SARS-CoV-2 primary strain-based vaccination exerts a protective effect against Omicron variants-initiated infection, symptom occurrence, and disease severity in a booster-dependent manner. Yet, the underlying mechanisms remain unclear. During the 2022 Omicron outbreak in Shanghai, we enrolled 122 infected adults and 50 uninfected controls who had been unvaccinated or vaccinated with two or three doses of COVID-19 inactive vaccines and performed integrative analysis of 41-plex CyTOF, RNA-seq, and Olink on their peripheral blood samples. The frequencies of HLA-DR <sup>hi</sup> classical monocytes, non-classical monocytes, and Th1-like Tem tended to increase, whereas the frequency of Treg was reduced by booster vaccine, and they influenced symptom occurrence in a vaccine dose-dependent manner. Intercorrelation and mechanistic analysis suggested that the booster vaccination induced monocytic training, which would prime monocytic activation and maturation rather than differentiating into myeloid-derived suppressive cells upon Omicron infections. Overall, our study provides insights into how booster vaccination elaborates protective immunity across SARS-CoV-2 variants.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37769658/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37769658</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.033>10.1016/j.cell.2023.08.033</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37769658</guid><pubDate> Thu, 28 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Shanhe Yu</dc:creator><dc:creator> Yingni Lin</dc:creator><dc:creator> Yong Li</dc:creator><dc:creator> Shijun Chen</dc:creator><dc:creator> Lina Zhou</dc:creator><dc:creator> Hejie Song</dc:creator><dc:creator> Cuiping Yang</dc:creator><dc:creator> Haiqing Zhang</dc:creator><dc:creator> Jianping Zhou</dc:creator><dc:creator> Shunchang Sun</dc:creator><dc:creator> Yanan Li</dc:creator><dc:creator> Juan Chen</dc:creator><dc:creator> Ruixue Feng</dc:creator><dc:creator> Niu Qiao</dc:creator><dc:creator> Yinyin Xie</dc:creator><dc:creator> Ruihong Zhang</dc:creator><dc:creator> Tong Yin</dc:creator><dc:creator> Saijuan Chen</dc:creator><dc:creator> Qingyun Li</dc:creator><dc:creator> Jiang Zhu</dc:creator><dc:creator> Jieming Qu</dc:creator><dc:date> 2023-09-28</dc:date><dc:source> Cell</dc:source><dc:title> Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine</dc:title><dc:identifier> pmid:37769658</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.033</dc:identifier></item><item><title> The local microenvironment drives activation of neutrophils in human brain tumors</title><link/> https://pubmed.ncbi.nlm.nih.gov/37769657/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231001120910&amp;v=2.17.9.post6+86293ac<description> Neutrophils are abundant immune cells in the circulation and frequently infiltrate tumors in substantial numbers. However, their precise functions in different cancer types remain incompletely understood, including in the brain microenvironment. We therefore investigated neutrophils in tumor tissue of glioma and brain metastasis patients, with matched peripheral blood, and herein describe the first in-depth analysis of neutrophil phenotypes and functions in these tissues. Orthogonal profiling... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 23:S0092-8674(23)00977-7. doi: 10.1016/j.cell.2023.08.043. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Neutrophils are abundant immune cells in the circulation and frequently infiltrate tumors in substantial numbers. However, their precise functions in different cancer types remain incompletely understood, including in the brain microenvironment. We therefore investigated neutrophils in tumor tissue of glioma and brain metastasis patients, with matched peripheral blood, and herein describe the first in-depth analysis of neutrophil phenotypes and functions in these tissues. Orthogonal profiling strategies in humans and mice revealed that brain tumor-associated neutrophils (TANs) differ significantly from blood neutrophils and have a prolonged lifespan and immune-suppressive and pro-angiogenic capacity. TANs exhibit a distinct inflammatory signature, driven by a combination of soluble inflammatory mediators including tumor necrosis factor alpha (TNF-ɑ) and Ceruloplasmin, which is more pronounced in TANs from brain metastasis versus glioma. Myeloid cells, including tumor-associated macrophages, emerge at the core of this network of pro-inflammatory mediators, supporting the concept of a critical myeloid niche regulating overall immune suppression in human brain tumors.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37769657/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37769657</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.043>10.1016/j.cell.2023.08.043</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37769657</guid><pubDate> Thu, 28 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Roeltje R Maas</dc:creator><dc:creator> Klara Soukup</dc:creator><dc:creator> Nadine Fournier</dc:creator><dc:creator> Matteo Massara</dc:creator><dc:creator> Sabine Galland</dc:creator><dc:creator> Mara Kornete</dc:creator><dc:creator> Vladimir Wischnewski</dc:creator><dc:creator> Joao Lourenco</dc:creator><dc:creator> Davide Croci</dc:creator><dc:creator> Ángel F Álvarez-Prado</dc:creator><dc:creator> Damien N Marie</dc:creator><dc:creator> Johanna Lilja</dc:creator><dc:creator> Rachel Marcone</dc:creator><dc:creator> Gabriel F Calvo</dc:creator><dc:creator> Rui Santalla Mendez</dc:creator><dc:creator> Pauline Aubel</dc:creator><dc:creator> Leire Bejarano</dc:creator><dc:creator> Pratyaksha Wirapati</dc:creator><dc:creator> Iván Ballesteros</dc:creator><dc:creator> Andrés Hidalgo</dc:creator><dc:creator> Andreas F Hottinger</dc:creator><dc:creator> Jean-Philippe Brouland</dc:creator><dc:creator> Roy T Daniel</dc:creator><dc:creator> Monika E Hegi</dc:creator><dc:creator> Johanna A Joyce</dc:creator><dc:date> 2023-09-28</dc:date><dc:source> Cell</dc:source><dc:title> The local microenvironment drives activation of neutrophils in human brain tumors</dc:title><dc:identifier> pmid:37769657</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.043</dc:identifier></item><item><title> Light the FIRE of revascularization in older patients with myocardial infarction</title><link/> https://pubmed.ncbi.nlm.nih.gov/37769442/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231001120910&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 28:ehad638. doi: 10.1093/eurheartj/ehad638. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37769442/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37769442</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad638>10.1093/eurheartj/ehad638</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37769442</guid><pubDate> Thu, 28 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Rocco Vergallo</dc:creator><dc:creator> Massimo Volpe</dc:creator><dc:date> 2023-09-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Light the FIRE of revascularization in older patients with myocardial infarction</dc:title><dc:identifier> pmid:37769442</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad638</dc:identifier></item><item><title> Low carbohydrate/ketogenic diet in the optimization of lipoprotein(a) levels: do we have sufficient evidence for any recommendation?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37769437/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231001120910&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 28:ehad635. doi: 10.1093/eurheartj/ehad635. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37769437/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231001120910&v=2.17.9.post6+86293ac">37769437</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad635>10.1093/eurheartj/ehad635</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37769437</guid><pubDate> Thu, 28 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Stanisław Surma</dc:creator><dc:creator> Amirhossein Sahebkar</dc:creator><dc:creator> Maciej Banach</dc:creator><dc:creator> endorsed by the International Lipid Expert Panel (ILEP)</dc:creator><dc:date> 2023-09-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Low carbohydrate/ketogenic diet in the optimization of lipoprotein(a) levels: do we have sufficient evidence for any recommendation?</dc:title><dc:identifier> pmid:37769437</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad635</dc:identifier></item></channel></rss>